INS and type 2 diabetes mellitus: However, in a clinical trial, T2DM patients treated with metformin were concurrently received either exenatide or insulin glargine, only the exenatide group lost body weight significantly and had maintained bone mineral density levels after 44 weeks of treatment [17], which is due to weight loss [18], and insulin administration may contribute to reduction in bone resorption [19].